Abnormal serum fatty acid profile in psoriatic arthritis.

Abnormal serum fatty acid profile in psoriatic arthritis. Arch Med Sci. 2019 Oct;15(6):1407-1414 Authors: Mysliwiec H, Harasim-Symbor E, Baran A, Szterling-Jaworowska M, Milewska AJ, Chabowski A, Flisiak I Abstract Introduction: Psoriatic arthritis (PsA) is a chronic inflammatory disease associated with higher risk of cardiovascular events and metabolic syndrome than psoriasis without arthritis. Fatty acids (FA) play an important role as signaling molecules in inflammatory and metabolic pathways. The aim of the study was to evaluate serum FA concentration in patients with PsA and to investigate the correlations of FA with the clinical and biochemical markers. Material and methods: We measured 14 FA serum concentrations by gas-liquid chromatography and flame-ionization detector after direct transesterification in 54 psoriatic patients (including 14 PsA patients) and 32 healthy controls. FA were divided according to their biologic properties into: saturated FA (SFA) and unsaturated FA (UFA), subdivided into monounsaturated FA (MUFA) and polyunsaturated FA (PUFA). Results: The results were correlated with Psoriasis Area and Severity Index (PASI), inflammatory and biochemical markers and lipid profile. We observed an abnormal FA profile in both psoriasis and PsA. We demonstrated lower concentrations of 10 FA in psoriasis and 7 in PsA. Patients with joint disease had a significantly higher percentage of SFA (p = 0.016) and MUFA (p = 0.001) and lower pe...
Source: Archives of Medical Science - Category: General Medicine Tags: Arch Med Sci Source Type: research

Related Links:

Conclusion: PsA is characterized by an increase in cardiovascular morbidity in relation with insulin resistance. Current treatments seem to improve this risk with a decrease in cardiovascular mortality in comparison with patients with plaque psoriasis but this requires confirmation in larger prospective studies.
Source: Joint Bone Spine - Category: Orthopaedics Source Type: research
Authors: Dalmády S, Kemény L, Antal M, Gyulai R Abstract Introduction: Psoriasis is a chronic autoimmune skin disease with strong genetic background and environmental triggers. Patients with psoriasis and psoriatic arthritis are at greater risk of developing other chronic and potentially severe comorbidities, such as psoriatic arthritis, hyperlipidemia, type 2 diabetes mellitus, obesity, metabolic syndrome, cardiovascular diseases or depression. Recently, accumulating epidemiologic, genetic and pathogenetic evidence indicates that psoriasis is also associated with periodontitis, a chronic progressive ...
Source: Expert Review of Clinical Immunology - Category: Allergy & Immunology Tags: Expert Rev Clin Immunol Source Type: research
Conclusions: The remarkable differences among the few available data on the association between GSTM1/GSTT1 polymorphisms and psoriasis suggest the need for further studies, on different and larger populations, to improve knowledge on the pathogenesis of psoriasis and possibly provide more precise and personalized prevention and treatment in the future. PMID: 31774007 [PubMed - as supplied by publisher]
Source: Free Radical Research - Category: Research Tags: Free Radic Res Source Type: research
Background: Psoriasis and psoriatic arthritis (PsA) are associated with a high prevalence of metabolic syndrome and increased risk of diabetes. Apremilast, an oral phosphodiesterase 4 inhibitor, was efficacious in the treatment of patients (pts) with moderate to severe psoriasis in the phase 3 ESTEEM 1 and 2 (EST) and phase 3b LIBERATE trials and in the treatment of pts with active PsA in the phase 3 PALACE 1 –3 trials (PAL). To explore the potential effect of apremilast on A1c concentrations, we assessed A1c in pts receiving placebo (PBO) or apremilast in a pooled analysis of EST, LIBERATE, and PAL.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research
ConclusionERAPSO revealed inadequate medical care of obese psoriasis participants with insufficient support for weight loss through diet or increased physical activity. Although psoriasis participants showed an intact self-perception of obesity, they seemed to lack intrinsic motivation to lose weight, highlighting the need for external support in losing weight via tailored programs. Since psoriasis severity correlates with impairment in diets and sports, treating psoriasis adequately may allow participants to follow weight loss programs more successfully.FundingNovartis Pharma GmbH, Nuremberg, DE.
Source: Dermatology and Therapy - Category: Dermatology Source Type: research
Conditions:   Psoriasis Vulgaris;   Psoriatic Arthritis;   Metabolic Syndrome Intervention:   Diagnostic Test: omentin, visfatin Sponsor:   Istanbul Medeniyet University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusions: It is very important to study immunologic mechanisms responsible for the presence and severity of psoriasis, in order to personalize the therapy in the future and optimize the effect of action on the basic disease and on concomitant disorders. PMID: 30858782 [PubMed]
Source: Advances in Dermatology and Allergology - Category: Dermatology Tags: Postepy Dermatol Alergol Source Type: research
AbstractPsoriasis is now recognized as an immune-mediated inflammatory dermatosis with increased risk for metabolic syndrome, its individual components, and cardiovascular disease. We quantitatively estimated malondialdehyde (MDA), lipoprotein-a (LP-a), lipoprotein ratios, comprehensive lipid tetrad index (CLTI), and atherogenic index (AI), and evaluated cardiovascular risk in 132 (M:F 94:38) patients with psoriasis aged 20 –79 years with chronic plaque psoriasis and equal number of age and gender-matched controls. Lipoprotein ratios, CLTI and AI were calculated using standard formulae. Cardiovascular 10-year ri...
Source: Archives of Dermatological Research - Category: Dermatology Source Type: research
Abstract BACKGROUND: Long-term therapy of psoriasis is impaired by gradual loss of effectiveness and treatment discontinuation. Identifying factors that affect biologic drug survival may help in treatment optimization. OBJECTIVES: To identify factors that predicted biologic drug persistence or discontinuation in a real-life setting. METHODS: We identified the studies of biologic persistence in psoriasis through a comprehensive, systematic literature search using pre-defined search criteria and screened by title/abstract then further by full-text review. Hazard ratio (HR) data were extracted for all avail...
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research
This study aimed to evaluate the prevalence of metabolic syndrome (MetS) and psoriatic arthritis (PsA) and to investigate HRQoL and the prevalence of hypertension, type 2 diabetes mellitus (T2DM), obesity and dyslipidemia. In a cross‐sectional design, patients d iagnosed with plaque psoriasis answered an interview and standardized questionnaires (Dermatology Life Quality Index questionnaire [DLQI], 36‐Item Short Form Health Survey [SF‐36] and EuroQol Five‐Dimension Questionnaire Three‐Level version [EQ‐5D‐3L]). Physical examination and several t ests to assess desired outcomes were performed by a dermatologis...
Source: The Journal of Dermatology - Category: Dermatology Authors: Tags: Original Article Source Type: research
More News: Arthritis | Biomedical Science | Cardiology | Cardiovascular | General Medicine | Heart | Metabolic Syndrome | Psoriasis | Psoriatic Arthritis | Rheumatology | Science | Study